Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01682304 · ClinicalTrials.gov registry record
Epigenomic Dysregulation in Preeclampsia-Associated Chronic Hypertension
A clinical trial, sponsored by Ohio State University.
- Completed
- Registry status
- 12
- Enrollment target
NCT01682304 is a clinical trial that has completed, run by Ohio State University. The registered enrollment target is 12 participants.
The verdict
NCT01682304 has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
Study Summary
Preliminary data from the investigator's lab identified novel patterns of differential DNA methylation in genes regulating cardiovascular and metabolic function in blood from women during the first trimester of pregnancy who were destined to develop preeclampsia (PE) in the third trimester. Further, common patterns of differential DNA methylation were found in the common genes from placental tissue at time of birth in the same women after diagnosis with PE, suggesting that the epigenomic patterns that predict pregnancy-induced hypertension may also underlie the development of chronic hypertension years after. It is unknown whether aberrant DNA methylation in pregnancy-induced hypertension is the mechanism by which chronic hypertension develops in these women remote from pregnancy nor is it known if hypertension remote from PE is as responsive to therapeutic treatment of hypertension compared to women who develop hypertension without history of PE. The investigators plan to objectively test the central hypothesis and attain the objective of this project
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01682304
The ClinicalTrials.gov registry entry for NCT01682304 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01682304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01682304 about?
NCT01682304 is a clinical study titled "Epigenomic Dysregulation in Preeclampsia-Associated Chronic Hypertension". Preliminary data from the investigator's lab identified novel patterns of differential DNA methylation in genes regulating cardiovascular and metabolic function in blood from women during the first trimester of pregnancy who were destined to develop preeclampsia (PE) in the third trimester. Further,...
What is the current status of trial NCT01682304?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2012-05. Estimated completion is 2014-03.
Who is sponsoring clinical trial NCT01682304?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.